Below you will find the program for both conference days, outlining the scheduled sessions and activities. For each session, timing, speakers and content are provided. Pending speakers will be added over time.
Moderators – Joanne Verweij & Jeremia Pyuza
> The anti-D divide
09:00 – Why are we here today?
Ellen van der Schoot (Sanquin, University of Amsterdam, the Netherlands)
09:10 – an HDFN patient journey in Africa and Netherlands
Rose Murage (Allohope Foundation, Kenya) & NL patient
09:30 – AFRICARhE: a Landscape Analysis & systematic review
Rafiki Mjema (KCMC, Tanzania) & Assefa Desalew (Haramaya University, Ethiopia)
09:50 – A systematic review on RhD immunization from India
Shamee Shastry (KMC Manipal,India)
10:10 – RhD prophylaxis & immunization in Latin America
J. Andrés Benavides Serralde (Universidad ICESI, Colombia)
10:30 – Coffee
> Polyclonal anti-D initiatives: past, present, future
> Experiences from Australia, South Africa and the Netherlands
11:00 – The Netherlands: in the past non-profit self-sufficient, female donors
Masja de Haas (Sanquin & LUMC )
11:10 – Rh program in Australia
Kobie von Wielligh (Australian Red Cross)
11:20 – Experiences from South Africa
Mashibe Nthlane (NBI SA)
> The future: blueprint for European plasma collection
11:30 – Steps to come to self sufficiency in Europe
Pierre Tibierghien (European Blood Alliance)
11:40 – Women – for – women: anti-D plasma donor recruitment
Eva Maria Merz (Sanquin Research, VU, the Netherlands)
11:50 – Role of European Medicines Agency and regulatory frameworks
Sandra Dang (European Medicines Agency, Amsterdam)
> The future in Africa
12:00 – AntiD plasma collection in Ethiopia
Ashenafi Amare (Ethiopian Blood and Tissue Service)
12:10 – Discussion on donor selection and donor recruitment
12:30 – Lunch
Moderators – Steve Spitalnik (US) & Abera Kenay Tura (UK)
Steps towards monoclonal development
13:30 – Sanquin monoclonal pipeline
Gestur Vidarsson ( Sanquin Research, UMCU, the Netherlands)
13:45 – Australian initiatives
Ian Wicks (The Walter and Eliza Hall Institute of Medical Research)
14:00 – Bharat Serums (RhoClone) experience
Speaker to be confirmed
14:15 – LFB experience
Philippe Mandon (LFB, France)
14:30 – Ethical challenges in monoclonal trials
Joanne Verweij (LUMC, the Netherlands) &
Heidi Matisonn (University of Cape Town, South Africa)
14:45 – Discussion
15:00 – Tea
> Parallel workshops: working towards a position statement
15:15 – Parallel workshops including:
Equitable access to anti-D, advocacy & policy pathways, cost-efficiency and dosing optimization, African plasma collection initiatives, research ethics of a monoclonal anti-D, patient involvement and donor recruitment strategies
16:30 – Plenary: summary of the afternoon and concrete action plans
17:00 – Closure
18:30 Drinks and dinner
0.9.00 – Introduction & welcome
Joanne Verweij & Masja de Haas & Enrico Lopriore
> Session 1: screening strategies
Moderator: Masja de Haas & Claudia Folman
09:10 — State of the Art from an international perspective: which women do we test for which red blood cell antibodies
The 7th John Gorman Lecture
Yanli Yi (Guangzhou Blood Center, Guangzhou, China)
09.30 — Variations in timing, frequency and methods – results from the Dionysus & questionnaire
Renske van ‘t Oever (LUMC and Sanquin, the Netherlands)
09:40 — 1 or 2 times screening, for all women or for subgroups only?
One screening timepoint for D-positives
Nuria Nogues Galvez (Immunohematology lab, Barcelona, Spain)
Two screening timepoints for D-positives
Edwin Masey, (Welsh Blood Service, Pontyclun, UK)
Second screening for subgroup of D-positives: the c-negatives
Claudia Folman (Immunohematology Expertise Center, Sanquin Diagnostic Serv., the Netherlands)
Discussion panel on set of statements with all speakers of session 1
10:15 — Fetal genotyping on cell free fetal DNA: replacing paternal typing?
Discussion is introduced by two short presentations on the rationale for their own program:
The European perspective
Frederik Clausen (Copenhagen University Hospital, Denmark)
The US perspective
Ken Moise (Dell Medical School, Texas)
Discussion panel on set of statements with all speakers of session 1
10:45 — Coffee
> Session 2: diagnostics and referral
Moderator: Masja de Haas & Joanne Verweij
11:10 — State of the Art from an international perspective: how to timely identify in the lab women at high risk and possibly needing intervention
Cecile Toly Ndour (National Reference Center Perinatal Hemobiology, Paris, France)
11:25 — Variations high risk identification, cut-offs/thresholds – results from the Dionysus & questionnaire
Marloes Kuijpers (LUMC, the Netherlands)
11:35 — Consensus Recommendations on antibody testing from a Modified Delphi Process in Canada
Gwen Clarke (University of Alberta)
11:50 — Is there added value of biological assays?
Claudia Folman (Immunohematology Expertise Center, Sanquin Diagnostic Serv., the Netherlands)
Discussion panel on set of statements with all speakers of session 1 & 2 on high risk identification
12:30 — Lunch
> Session 3: antenatal management
Moderator: Joanne Verweij
13:30 — State of the Art from an international perspective: antenatal treatment – past, present and future
Ken Moise (Dell Medical School, Texas, USA)
13:50 — Variations in antenatal management – results from the Dionysus & questionnaire
Marloes Kuijpers (LUMC, the Netherlands)
Discussion panel
14:00 — Delay of IUT with IVIG and/or plasmapheresis
Two short presentations on the rationale for their own management strategy:
Pro
> Speaker to be confirmed
Contra
> Roland Devlieger (UZ Leuven, Belgium)
Discussion panel
14:30 — The IUT approach
Three short presentations on the rationale for their own management strategy:
Placental insertion only
Jean-Marie Jouannic ( Sorbonne University Paris, France)
Intra-hepatic only
> Speaker to be confirmed
50/50 placental insertion/intra-hepatic
Femke Slaghekke (LUMC, the Netherlands)
15:00 — Tea
> Session 4: postnatal management
Moderator: Enrico Lopriore
15:20 — State of the Art from an international perspective: postnatal management
Tim Bahr (University of Utah, USA)
15:30 — Variations in postnatal management – results from the Dionysus & questionnaire
Derek de Winter (LUMC, Netherlands)
Discussion panel
15:40 — Delay the induction of labor >38 weeks
Two short presentations on the rationale for their own management strategy:
Pro
> Enrico Lopriore (LUMC, the Netherlands)
Contra
> Roland Devlieger (UZ Leuven, Belgium)
Discussion panel
16:10 — IVIG to prevent exchange transfusion
Two short presentations on the rationale for their own management strategy:
Pro
> Jana Lozar Krivec (Ljubljana University, Slovenia)
Contra
> Maria Pessoa Dos Santos (Universidade Federal do Rio de Janeiro, Brazil)
> Plenary workshop & closing session
16:40 — Barriers, facilitators and best practices across countries
17:00 — Closing Session
Towards a coordinated global research and policy agenda for HDFN